Characteristics, Management, and Outcomes of Community-Acquired Pneumonia due to Respiratory Syncytial Virus: A Retrospective Study

Table 2

Management of patients admitted with community-acquired pneumonia due to respiratory syncytial virus.

Variable	All patients	ICU admission	No ICU admission	value
Mechanical ventilation, (%)	13 (16.2)	13 (68.4)	0 (0)	<0.001
Use of steroids, (%)	43 (53.7)	14 (73.7)	29 (47.5)	0.065
Initial daily dose (in mg prednisone equivalent), median (IQR)	40.0 (32.5, 75.0)	55.0 (36.3, 100.0)	40.0 (30.0, 40.0)	0.02
Antimicrobial therapy, (%)
No initial antibiotic	3 (3.8)	1 (5.3)	2 (3.3)	0.562
	32 (40.1)	5 (26.3)	27 (44.4)	0.190
Piperacillin-	30 (37.6)	9 (47.4)	21 (34.5)	0.416
	3 (3.8)	2 (10.6)	1 (1.6)	0.139
Oseltamivir, (%)	61 (76.3)	15 (78.9)	46 (75.4)	0.752

IQR: interquartile range.